Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 | P31751 | 20/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.78 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675468 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL18797669 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17424823 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| Hydrochloric Acid SCHEMBL192532 | 0.99 | AKT1 (0.98) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| Hydrochloric Acid SCHEMBL192533 | 0.99 | AKT1 (0.98) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL22149954 | 0.93 | AKT1 (0.86) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17424851 | 0.91 | AKT1 (0.83) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL192686 | 0.91 | AKT1 (0.83) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL192927 | 0.91 | AKT1 (0.83) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL192687 | 0.91 | AKT1 (0.83) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | claimed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | claimed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | claimed |
| US-8853199-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | claimed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | claimed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | claimed |
| US-20250161322-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | GENENTECH INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12083129-B2 | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4294393-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND IPATASERTIB | Genentech, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230330106-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | GENENTECH INC (US) | 2023-10-19 | — | — | US | disclosed |
| US-11701356-B2 | Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11576919-B2 | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant | GENENTECH, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210046086-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | GENENTECH, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2020210337-A1 | DEGRADATION OF AKT BY CONJUGATION OF ATP-COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200197396-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR | GENENTECH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| EP-2694485-B1 | COMBINATION OF AKT INHIBITOR COMPOUND AND VEMURAFENIB FOR USE IN THERAPEUTIC TREATMENTS | GENENTECH INC (US) | 2017-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-20200197396-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR | PDCD1LG2, PDCD1, PDCD10 | AKT1 28/4885AKT2 11/4885AKT3 13/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885AKT3 791/4885 |
| US-20210046086-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | CDK4, CDK6, PIK3CA | AKT1 98/4885AKT2 88/4885AKT3 99/4885 |
| US-12083129-B2 | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant | CDK4, CDK6, PIK3CA | AKT1 98/4885AKT2 88/4885AKT3 99/4885 |
| US-11576919-B2 | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant | CDK4, CDK6, PIK3CA | AKT1 98/4885AKT2 88/4885AKT3 99/4885 |
| US-20230330106-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | CDK4, CDK6, PIK3CA | AKT1 98/4885AKT2 88/4885AKT3 99/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-11701356-B2 | Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor | PDCD1LG2, PDCD1, PDCD10 | AKT1 28/4885AKT2 11/4885AKT3 13/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20250161322-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | CDK4, CDK6, PIK3CA | AKT1 98/4885AKT2 88/4885AKT3 99/4885 |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.